

AGENDA

AUDIT COMMITTEE MEETING September 9, 2021 9:00 am – 10:00 am NH Insurance Department, Walker Building, Room 274 21 South Fruit Street, Concord, NH Via Front Entrance

** Note: While masks are not required by the State, the NHVA respectfully requests that you wear a mask if you are attending the meeting in person given the recent rise in COVID cases. **

To participate by Zoom, please register here:

https://nhvaccine.org/event/nhva-audit-committee-meeting-september-9-2021/

Committee Members: David Sky, Chair, Susan Tenney, Vice Chair, Elizabeth Daly, Jason Margus

Administrator Staff: Patrick Miller, Erin Meagher, Ashley Ithal

Guests: Leslie Walker, Mason+Rich PA

9:00am	1. Call to Order (D. Sky)
9:00am-9:10am	2. Review and Accept the August 25, 2021 Meeting Minutes – Vote (D.
	Sky)*
9:10am-9:40am	3. CY2022 Assessment Rate Discussion and Board Recommendation—
	Vote (P. Miller)*
	Guest: Leslie Walker, Mason+Rich, PA
9:40am-9:50am	4. Other Business
9:50am-10:00am	5. Public Comment Period
10:00am	6. Call to Adjourn (D. Sky)

^{*} indicates an attachment



MINUTES

Audit Committee Meeting August 25, 2021

9:00 a.m.

NH Insurance Department, Walker Building Room 274, Concord, NH Presiding Officer: David Sky, Chair, Audit Committee

A meeting of the Audit Committee of the Board of Directors of the New Hampshire Vaccine Association (NHVA) with a quorum present was held at the NH Insurance Department, Walker Building, Room 274, Concord, NH and remote access for the public was provided via Zoom Webinar.

12 13

Mr. Sky, Chair, called the meeting to order at 9:02 a.m.

14 15 16

1. Welcome and Introductions

Attendance – The following individuals attended the meeting:

17 18

Committee Members: Other Attendee & Administrative Staff:

David Sky, NHID, Chair Susan Tenney, HPHC, Vice Chair Beth Daly, NH DHHS Jason Margus, Anthem

Anne Marie Mercuri, NH DHHS
Patrick Miller, Helms & Company
Erin Meagher, Helms & Company
Keith Nix, Helms & Company
Ashley Ithal, Helms & Company
Karen Carew, Carew & Wells, PLLC

Leslie Walker, Mason + Rich, P.A.

Members of the Public

Laura Condon, Bedford Representative Linda Gould, Bedford Jessica Kliskey, Stratham

19 20

Mr. Miller announced that he was recording the meeting for the purpose of drafting minutes. Ms. Condon announced she would be recording the meeting.

21 22 23

Mr. Sky opened the meeting reciting NHVA's statement regarding public commentary during meetings.

242526

2. Review and Acceptance of April 28, 2021 Meeting Minutes

28 29 30

27

Mr. Sky asked the Committee if anyone had any questions or changes to the April 28, 2021, meeting minutes. No questions or changes were identified.

31 32

VOTE RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously **VOTED:** To accept the April 28, 2021, Audit Committee meeting minutes as presented.

33 34

3. Review and Vote to Recommend Acceptance of the FY2021 Audited Financials

35 36 37

38

39

Mr. Sky invited Ms. Carew to review the audited financial statements. Ms. Carew began with a review of the governance letter. Ms. Carew summarized several significant estimates examined when preparing the financial statements. The first is the estimate of the vaccine expense, including the projected amount requested by the State of New Hampshire, and the underlying assumptions that management considers in developing the estimate to determine if reasonable. The second was an examination of rate stabilization and the \$5M that has been designated



for that purpose. Finally, there is an estimate of any balance due or accounts receivable. Typically, there are none, however, this past quarter there was one small receivable due as of June 30th and it has since been received. Ms. Carew's determination found the three estimates were reasonable.

Ms. Carew reported there were no difficulties in performing the audit or in working with management. There were no misstatements that were material to the financial statements and there were two very small timing adjustments that were discussed with management and have been included with the letter. Ms. Carew stated that she requested and received a representation letter from the Mr. Sky and Mr. Miller on behalf of the Association to make sure that it is understood that the financial statements are the Association's responsibility and Carew & Wells is providing an opinion on them.

Ms. Carew stated that several years ago there were a few, minor management recommendations made to strengthen internal controls. All recommendations were implemented as suggested. This year there are no recommended changes for controls. Mr. Miller reported that Helms & Company fully updated the financial procedures documentation prior to the start of the audit. Ms. Carew commented that they do review the controls every year as part of the audit process, and it was clear that a tremendous amount of time was spent updating the document.

Ms. Carew reviewed the Auditor's Report and stated that Carew & Wells provided a clean opinion. She stated that she does not believe there are any misstatements or changes that need to be made to the financial statements to confirm with Generally Acceptable Accounting Principles. Ms. Carew provided a brief overview of new requirements for the Auditor's Letter with additional sections making sure there is a clear understanding about how the audit is performed.

Ms. Carew asked the group if anyone needed her to review the financial statements themselves. There being no questions, she highlighted two items of interest beginning with the Notes on page 10 regarding TRICARE. The outstanding balance for the TRICARE settlement is at \$468,630. It is anticipated that this will be collected in fiscal year 2022 and therefore will be settled in the upcoming year. Finally, she directed the group to Subsequent Events on page 12. As was done last year, there is mention of the ongoing pandemic.

Mr. Sky asked if there was a motion to meet in non-public session with Ms. Carew.

VOTED:

VOTE RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously **VOTED:** To move to a non-public session with Ms. Carew.

All non-Audit Committee members left the room and the Zoom to enable the Audit Committee to enter into non-public session with Ms. Carew to discuss the audit. After the meeting, Mr. Sky provided the following meeting minutes for the non-public session:

Committee members engaged in a discussion with Ms. Carew regarding any issues or concerns she had in conducting the audit. Ms. Carew stated that there were no issues or concerns.

VOTE RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously

To adjourn the non-public session.

VOTE RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously

 VOTED: To recommend to the Board of Directors to accept the FY2021 Audited Financials.

Mr. Miller stated that he included in the meeting packet the final FY2021 Statement of Cash Flow, Statement of Financial Position, and Statement of Changes in Net Assets for the Committees reference. The statements correspond to the audit, and they are very similar to what was shared at the June meeting, however, the assessment



revenue has been updated along with a few other changes. Mr. Miller stated that covered lives are similar to lives for the prior quarter, 161,564 for quarter two and a slight increase to 161,828 for quarter three.

4. CY2022 Assessment Rate Initial Assumptions Discussion

Mr. Miller introduced Ms. Walker from the accounting and auditing firm Mason+Rich. Ms. Walker was retained by Helms & Company to review and refine the assessment rate setting process. Based on several factors, including the State no longer maintaining credit balances for overpayments made by the Association, it made sense to do a full review.

Mr. Miller stated that the goal today is to review a set of trends, review the model assumptions, review the model output, and then discuss specific questions with the Committee. This will allow for additional revisions to be made between now and the Audit Committee and Board meetings in September.

Mr. Miller began by outlining the assessment process goals achieved over the past several years and the focus for calendar year 2022. Now that the goal of eliminating funds held by the State was met in 2021, in 2022, the process will address:

- the historical swings in payments to the State,
- incorporating the concept of zero funds held at the State,
- the modeling of a COVID assessment reserve,
- the conclusion of the TRICARE specific assessments, and
- the simplification of the model back-end tool.

Mr. Miller briefly reviewed the FY2021 Notable Fiscal Events slide including the TRICARE revenue that will be going away next fiscal year. The impact of this will be close to half a million dollars per year going forward. The historical trends charts were also briefly reviewed including *Shrinking Assessed Lives and Variability in Assessed Rates* which reflects a (0.2%) decline in covered lives. The impact of COVID was less than expected. We are paying attention to these numbers because while overall costs for vaccines are increasing slightly each year, covered lives are also declining.

Mr. Miller then reviewed trends for State/carrier split of expenditures, interest rate changes on investments, unemployment trends, and Medicaid enrollment. Notably, we have achieved a higher rate of return on the funds invested by Bank of New Hampshire than those in the ICS account. We continue to seek higher yielding investments within our investment policy parameters. Unemployment continues to remain low, yet Medicaid enrollment has increased.

Mr. Miller reviewed the assumptions contained in the model. These include:

- the Board's commitment to keeping rates stable,
- 10% reserve per RSA 126-Q:4 II.(c),
- \$5M assessment reserve fund,
- potential COVID assessment reserve for FY2023-2024,
- DHHS not holding excess funds,
- no reimbursement for DHHS' administrative cost request
- carrier support of 60%,
- interest rate at 0.9%,
- assessed lives decline of 0.05% per quarter,
- TRICARE rate remaining at \$14.82 into 2022 anticipating the paydown will be completed in approximately four quarters,
- 139 a 4% increase to the Administrative budget, and
 - no assessment interest payments.



Mr. Miller then reviewed the *SFY202-2024 Rate Model*. An assessment placeholder for COVID-19 vaccine payments has been put in place understanding that the Federal Government is currently paying for these vaccines, but long term it is believed that this will end. Many state vaccine programs are planning for this. A placeholder of \$500K for each of fiscal years 2023 and 2024 has been assumed in the model, and this can be lowered, raised, or eliminated based on what Committee members feel is appropriate. As explained earlier, interest rates are projected to remain low and has been assumed at 0.9%; the ultimate impact to the model is small. Although the economy is improving and we anticipate an increase of covered lives, they are likely to continue to decline. The Committee held a discussion regarding the model's covered live estimates, and they concluded that they are low and should be increased. Mr. Margus asked if anyone in the group had any expectation of there being a Medicaid disenrollment event next year when the public health emergency ends? He has heard of maintenance of eligibility requirements that are happening now that contributed to the increase with Medicaid. Mr. Miller explained that the disenrollment is expected to begin later this fall, but it happens based on when you enrolled so it does not all happen on one day. This can be clarified, prior to the meeting in September. The Committee discussed the expected decline in Medicaid rolls when the Federal state of emergency is lifted. Mr. Miller stated he would find additional information on the expected change in enrollment.

Mr. Miller reviewed the variability of the amount of the prior June payments NHVA has made to the State. One of the goals is to make this payment more level each year. Beyond next year, the TRICARE revenue will end which will have a negative impact of nearly half a million dollars per year. The request from DHHS assumes a CDC credit of \$2.5M, but the model assumed \$2.8M; this will be corrected in the next version of the model. With the assumptions outlined, the CY 2022 rate would be \$7.20, and it is currently \$6.25 which was reduction from a rate of \$6.80 the year prior. One way to reduce the proposed rate of \$7.20 would be to use some of the \$5M assessment reserves.

Mr. Margus asked for clarification from Mr. Miller relating to the total covered lives. Mr. Miller confirmed that overall, we have been seeing a reduction of lives of approximately 0.2% per year. Current projections are based on where we are now vs. from where we were two or three quarters ago. The Committee agreed that the current model's covered lives show too steep of a decline and should be revised.

After an extensive discussion, it was agreed that Mr. Miller & Ms. Walker had provided the appropriate assumptions in developing the assessment rate for calendar year 2022 with a few edits to be undertaken. The Committee directed them to revise the model to include rates in the range of \$6.80-8.00 for discussion at the September 9, 2021 Audit Committee meeting.

5. Other Business

Mr. Sky asked the Committee members if anyone had any other business to discuss. There were none.

6. Public Comment

Mr. Sky asked if any members of the public wished to speak, and Ms. Condon indicated she did wish to provide a statement. Ms. Condon expressed concern that the Association continues to entertain DHHS' request for administrative support to support their registry program and staff. Ms. Condon referenced a letter from Attorney Mark McCue to NHVA dated September 5, 2018 which provided guidance for the Association on this reimbursement request. Ms. Condon also expressed concern regarding NHVA's authority to expend or reserve funds for a COVID-19 vaccine. Mr. Sky thanked Ms. Condon for her comments, asked the group if there was any other business and hearing none, asked for a motion to adjourn.

7. Adjournment

VOTE RECORDED: On a motion by Ms. Tenney, seconded by Ms. Daly, it was unanimously

VOTED: To adjourn the Audit Committee meeting at 10:41 a.m.



195 Respectfully submitted by
196 Patrick Miller, Helms & Company, Inc.
197 August 31, 2021

#





CY2022 Rate Setting

NHVA Audit Committee Meeting September 09, 2021 NH Insurance Department Walker Building, Room 274

Materials Updated September 1, 2021



Contents

- 1. Process
- 2. Historical Trends
- 3. NH DHHS Data and NHVA Administrative Budget for Assessment Process
- 4. Rate Assumptions and Assessment Rates



1. Process



Assessment Process Development History

CY2019

- Helms Simplified Prior Process
- Added TRICARE Lives to Assessment Process
- One Time Administrator Change Costs Absorbed
- Multi-Year Cash Flow / Assessment Rate Model Developed

CY2020

- Appropriated \$5M
 Reserve Fund
- Accounted for TRICARE Administrative Payment in Model


CY2021

- Assumed COVID-19Covered LivesAdjustment Factors
- Reduced Funds Held by NH DHHS to Zero

CY2022

- Addressed Swings in Payments to NH DHHS
- Addressed Conclusion of TRICARE Specific Assessments
- Simplified Model Back-End Tool

CY2022 Assessment Rate Setting Process Timeline





Review of FY2021 Notable Fiscal Events


- 1. Notable revenues in FY2021:
 - TRICARE specific assessment receipt— \$470,102
 - Assessment interest recoupment \$566
 - ICS and bank interest income \$55,827
 - Investment interest income \$60,183
 - Dividend income \$39
 - Realized gain \$800
- 2. Notable expenses in FY2021:
 - Investment advisory fees \$20,280
 - Unrecognized loss \$21,277
- 3. COVID Impact to Covered Lives Less Than Expected
 - 459,000 projected vs. FY2021Q3 = 485,484 & FY2021Q4 = 483,057



2. Historical Trends




Shrinking Assessed Lives and Variability in Assessed Rate



Source: NHVA KidsVax® reconciliation spreadsheet, 09-06-2018; NHVA Data August 2021 Note: Total Assessed Lives reflects CY2019 Tufts recovery activity and EBPA refund activity



Increasing State Vaccine Expenditures and Stability in Payer Proportion






Bank of New Hampshire Analysis

(as of August 18, 2021)

- ICS rate changes
 - July 2018 1bps
 - Nov 2018 200bps ← Helms negotiated new rate
 - Jan 2020 180bps
 - Mar 2020 50bps
 - Oct 2020 40bps
 - Jan 2021 30bps



- Laddered CD portfolio performance
 - Since March 2020 \$8.6M invested average yield 1.41%

← Pandemic began;


Federal rate plunged

- \$4.217M matured with average yield 1.47%
- \$4.338M still invested with average yield 1.32%
 - \$2.597M matures or is callable by Aug 2022 with average yield of 1.39%



Economy is Recovering but is Not Back to Pre-Pandemic Levels

US and NH Unemployment Trends




https://www.nhes.nh.gov/elmi/statistics/laus-data.htm



Medicaid Child
Enrollment is Leveling
Off but Higher than
Pre-Pandemic

NH Medicaid Enrollment



Source: NH DHHS



3. NH DHHS Data and NHVA Administrative Budget for **Assessment Process**

New Hampshire Vaccine Association NH DHHS Tab C Received 08-18-2021

		recast for SFY 2	Y 22 nization Program	\Box				—	+				+			-				
Actual Doses for SFY 21	New nampain	7e IIIIIIuiiiza	JUON Frogram	+							+ + +	SFY 21 Total Cost					SFY 22 Total Projected Cost	,		
VACCINE	2020 Price per Doses Cost	s 1st Qtr Totals	Total	2nd qtr totals	Total	3rd qtr totals	Total	Est 4th qtr totals	Cost	s Total	Total ordered in SFY 21		.05% wastage		Roundings	2021 Price Per Doses Cost		Private		
DT	\$ 56.69						0 \$ -		1 \$ 59.45			7 -,		0 10		0 \$ 59.45			7 -,0.0.0	
ACTHIB	\$ 9.48		,																	
HIBERIX	\$ 9.46													0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0						
DAPTACEL INFANRIX	\$ 18.07 \$ 18.67																			
INFANRIX ENGERIX B	T -0.0.																			
RECOMBIVAX HB																				
RECOMBIVAX HB HAVRIX	\$ 12.30 \$ 20.52																			
VAQTA	\$ 20.52																			
IPOL	\$ 13.55				,															
KINRIX	\$ 41.31																			
QUADRACEL	\$ 40.66																			
M-M-R II	\$ 21.22				,		, , , , , , , , , , , , , , , , , , , ,					,								
PROQUAD	\$ 131.40						,													
PEDIARIX	\$ 59.05																7	\$ 90.05		
PENTACEL	\$ 59.42																3 \$ 1,457,740.00			.d
Vaxelis***NEW for FY 22	\$ -		0 \$ -	0 \$		0 :			0 \$ 91.59		0 \$		0							
PNEUMOVAX 23	\$ 56.30	30 42	2 \$ 2,364.60	50 38 \$	3 \$ 2,139.40	0 24	4 \$ 1,351.20	0 31	31 \$ 62.08	08 \$ 1,924.48	48 135 \$	\$ 7,779.68		1 136	36 100	0 \$ 62.08	3 \$ 6,208.00	\$ 110.45	\$ 14,985.30	30
PREVNAR 13 TM	\$ 137.01										.60 45620 \$	\$ 6,381,962.60	0 228	28 45848						
ROTARIX	\$ 94.69							0 1070										\$ 127.03		.3
ROTATEQ	\$ 70.49	19 6030	0 \$ 425,054.70	70 5490 \$	\$ 386,990.10	0 7390			50 \$ 74.73	73 \$ 385,606.80	.80 24070 \$	\$ 1,718,572.70	70 120	20 24190			3 \$ 1,808,466.00	\$ 87.88	\$ 2,125,847.96	96
VARIVAX	\$ 104.09																			
Adolescent					·														\$	
ADACEL	\$ 31.75			,			7 00,000					7,-:				· · · · · · · · · · · · · · · · · · ·	,			-
BEXSERO	\$ 135.48																			
BOOSTRIX	\$ 32.24																			
GARDASIL9	\$ 178.14																			
MENACTRA	\$ 93.45																, , , , , , , , , , , , , , , , , , , ,			
MENVEO	\$ 94.84																			
TENIVAC	\$ 20.60								31 \$ 21.77		+									
TRUMENBA	\$ 108.95				7	-	· · · · · · · · · · · · · · · · · · ·		10 \$ 119.93	, , , , ,				2 462	62 500	0 \$ 119.93				-
	+	+	\$ 7,907,418.17	+	\$ 6,158,637.51	+	\$ 7,279,751.95	+	+	\$ 5,227,193.55	, ,	\$ 26,573,001.18	4	+	+		\$ 28,774,603.10	.+	\$ 40,228,686.11	11 -28%
				\pm			+				###					te Doses to Purchase	2			
		1ct Otr		and atr		nd nee		4th atr				· · · · · · · · · · · · · · · · · · ·			Influenza ordered for	- 2022 Price				
Influenza Vaccine		1st Qtr		2nd qtr totals		3rd qtr totals		4th qtr				Spent this Season VFC and State	1			2021-2022 Price		Privat	= +	
Influenza Vaccine SANOFL 5 flu	\$ 13.50	Totals 50 8260	0 \$ 111,510.00	1010.0		10.10.0			50 \$ 13.50	50 \$ 675.00			.+	+	Next Season p	per Dose 0 \$ 13.76	5 \$ 605,440.00		te Price*	00 SANOFI.5 flu
					,									+						
GSK .5 fluarix GSK .5 Flulaval	\$ 13.75 \$ 13.75								0 \$ 13.75 20 \$ 13.75		60600 \$.00 38810 \$			+	32500 25000					00 GSK .5 fluarix 00 GSK .5 Flulaval
GSK .5 Flulaval Flucelvax	\$ 13.75 \$ 16.02						0 \$ 23,925.00 0 \$ -		0 \$ 16.02		.00 38810 \$			+	25000					00 GSK .5 Flulaval 00 Flucelvax
Flucelvax	\$ 16.02						0\$ -		0 \$ 16.02		1370 \$			+	400					00 FluceIvax 00 Flumist
Fluithst	3		\$ 896,195.60		\$ 1,034,808.90		\$ 77,790.00		\$ 20	\$ 950.00						\$			\$ 1,883,554.00	
* CDC Online price list 4/1/2			-	++		+		+	+	<u> </u>	++		+	+		<u> </u>	\$ 1,434,154.00	,		
Actual TOTAL pediatric dose		aken from m	nonthly Spend Plan Re	eport			,					\$ 28,582,745.68	4			·	\$ 30,208,757.10		\$ 42,112,240.11	11 -289
		4	+	$\downarrow \longrightarrow$	·		+	+	-		+	. '	<u> </u>				+	4		
		+		+											+			,+		
			+				+	\Box					VSC Estim	-t-d (last year)	Vaccine Funds Cont	Libertian	\$ (10,907,515.00)	This is how much we		
				\pm								·		nated (last year) Va d State Funds Cont		ribution	\$ (10,907,515.00)	INIS IS HOW INGG	spent idst year.	
		4	+	\perp	<u> </u>	1	+	+	1		\perp		- timated	dit			63 500 000		10/4	_
		++		++		++		+	+		++			d CDC credit d cost of vaccine af	after CDC credit		\$2,500,000 \$ 27,708,757.10	Final amount available	e on 10/1.	+
updated 07/21/21; revised 0	. 00/10/2021	\perp	+				+	\Box	-					timated Cost			\$ 16,625,254.26	COV of total estima	ated expense after CDC	nodit
R:\OCPH\FCH\Immunization		CINE DISTRIP	ALITION PURCHASING	ACCOUNTA	ARII ITY\DISTRIBUTI	ON Data Anal	vsis\SFY 22	+	+	+	++			timated Cost NHVA revenue froi	rom prior SFYs		\$ 15,525,254.20	60% Of total estimate	d expense after CDC	_ crean.
1.10011.1.2	(0.025	10.5.5	non_r	10000	Livi qui i	100	13 (5. 1 ==				+				ative Costs Request	st	\$ 484,346.00	See worksheet e for d	r detail.	
		1						1						d NHVA funds need			\$ 17,109,600.26		, cca	



NH DHHS Tab D Received 08-18-2021

			SFY21	SFY20	SFY19	SFY18	SFY17	SFY16	SFY15	SFY14	SFY13	SFY12	SFY11	SFY10	SFY09	SFY08
	_	Source	2020/2021	2019/2020	2018/2019	2017/2018	2016/2017	2015/2016	2014/2015	2013/2014	2012/2013	2011/2012	2010/2011	2009/2010	2008/2009	2007/2008
Actual Total exp	+	4+7				, ,						\$21,707,838	_	\$28.121.414		\$25.454.043
Actual Lotal exp		4+/	\$26,067,468	\$26,126,101	\$26,837,646	\$26,377,918	\$24,657,418	\$24,741,423	\$26,092,637	\$20,945,469	\$21,918,042	\$21,/07,838	\$21,961,081	\$28,121,414	\$17,820,721	\$ 25,454,043
	_															
	_															
VFC	1				\$11,071,713					\$ 8,070,843				\$11,624,679	· , ,	\$ 8,588,458
317 - not used for children	2	CDC Mon Rpt	not provided	not provided	not provided	not provided	not provided	not provided	not provided	not provided	\$ 156,375	\$ 920,358	\$ 720,612	\$ 1,676,638	\$ 735,871	\$ 2,219,343
State Funds	3	St. Ap(5178-513)	\$ 105,300	\$ 103,178	\$ 273,969	\$ 293,211	\$ 392,339	\$ 302,821	\$ 206,762	\$ 460,501	\$ 482,467	\$ 320,494	\$ 492,762	\$ 573,306	\$ 213,821	\$ 422,798
TOTAL GOV'T EXPENDED	4	1+2+3	\$11,012,815	\$10,876,797	\$11,345,682	\$10,622,944	\$11,652,089	\$ 9,497,360	\$ 8,777,542	\$ 8,531,344	\$ 8,190,532	\$ 8,956,773	\$ 8,763,261	\$13,874,623	\$ 5,952,189	\$11,230,599
beg balance	5	State Approp	\$ 3,224,124	\$ 6,722,035	\$12,979,343	\$ 9,915,172	\$ 3,267,370	\$ (1,107,266)	\$ 3,797,531	\$ 207,631	\$ 3,042,624	\$ 6,102,932	\$ 7,039,214	\$12,293,560	\$ 7,759,278	\$ 4,919,231
revenue from NHVA*	6	State Approp			\$ 9,234,656			\$19,618,699		\$16,004,025	\$10,892,517	\$ 9,690,757	\$12,261,538	\$ 8,992,444	\$16,402,814	\$17,063,492
		 	, , ,				. , ,	. , ,		, ,	, ,			. , ,	, ,	
Vaccine Insurers expended	7	State Approp	\$15,054,653	\$15,249,304	\$15,491,964	\$15,754,974	\$13,005,330	\$15,244,063	\$17.315.095	\$12,414,125	\$13,727,510	\$12,751,065	\$13,197,820	\$14,246,791	\$11.868.532	\$14,223,444
	-		+ ==,== :,===	+//	7 20, 10 2,00	+	+ ==,===,===	+	+ =: /0=0/000	7, :- :,	<i>+</i> ,,	+	+ 10,10.,010	+ = .,=,	+,,	7 = 1,1=2,1
		+														
vear end encumbered	8	State Approp	\$ 3,734,347	\$ 3 284 045	\$ 214.014	\$ 4 119 258	\$ 3,912,837	\$ 5,360,641	\$ (1 217 018)	\$ 4 922 400	\$ 2 278 387	\$ 3.498.954	\$ 4 183 155	\$ 2,658,211	\$ 2,636,659	\$ 5,038,824
7	9		\$ (3,734,347)	. , ,	\$ 6,508,021					\$ 1,124,869				\$ 4,381,002		\$ 2,720,454
TOTAL BAL FORWARD	10	(5+6) -7	\$ (3,734,347)	. , , ,	. , ,	\$12,979,343		, , ,		\$ 3,797,531	. , , ,	\$ 3,042,624	. , ,	\$ 7,039,213	. , ,	
TOTAL BAL FORWARD	10	(3+0) -7	\$ -	\$ 3,224,124	\$ 6,722,033	\$12,979,343	\$ 9,915,172	\$ 3,207,370	\$ (1,107,200)	\$ 3,797,331	\$ 207,631	\$ 3,042,624	\$ 6,102,932	\$ 7,039,213	\$12,295,500	\$ 1,759,279
CDC end of fiscal year credit	11	CDC Vtracks	\$2,823,837	\$2 804 834	\$ 1,856,544	\$ 4 282 619	\$ 3 564 068	\$ 4 377 668	not provided	not provided	not provided	N/A	N/A	N/A	N/A	N/A
Reimbursement from Providers and Excise Tax	64	State Approp	\$2,023,037	72,004,034	ŷ 1,030,344	7 4,202,013	\$ 19,863	\$ 13,916		\$ 29,970	\$ 119,460	N/A	14/74	14/74	NA	11/7
Added into this account	UA	State Approp					7 13,803	ÿ 13,310	y 37,311	\$ 23,370	ÿ 113,400					
Added into this account	_	C	+h D-h (02 27	1 4027 -1:1		l	16, 2021		10 2021							
	-	Source: From Be	eth Daiy 603-27	1-4927 elizat	etn.daiy@dnns	.nn.gov on Au	gust 16, 2021; r	evised August	18, 2021.							
Note: NHVA as % of total budget			57.75%	58.37%	57.72%	59.73%	52.74%	61.61%	66.36%	59.27%	62.63%	58.74%	60.10%	50.66%	66.60%	55.88%
Note. Milva as 70 of total budget			37.73/0	36.37/6	37.72/0	35.73/6	32.74/0	01.01%	00.30%	35.27/6	02.03%	36.74/0	00.10%	30.00%	00.00%	33.86%



NH DHHS Tab E

Expense	Description	Total Cost	Amount Requested from NHVA
Immunization Information System	System utilized to order vaccines, document individual doses administered and show insurance coverage		
	for individuals vaccinated. System also provides quality assurance measures with vaccine forecasting and		
	reminder/recall abilities.	\$360,063.00	\$216,037.80
Vaccine Accountability Coordinator			
	Responsible for the purchase and distribution of all vaccines within the program. This position manages		
	Vaccine For Children (VFC), 317, and state/local vaccine funding. This individual tracks vaccine inventory,		
	vaccine distribution and administration, vaccine wastage, trends, all of which informs forecasting. This		
	postion plays a key role during the influenza season by closely tracking flu vaccine expenditures and		
	distribution to ensure the vaccines are in the right quantities and the right location, allowing for		
	successful clinic outcomes. This position works directly with the Public Health Regions to plan vaccine		
	distribution for Pandemic Exercises or vaccine-preventable disease outbreaks. The position collaborates		
	with the Immunization Information System (IIS), Vaccine Data Coordinator to provide vaccine ordering		
	management system training for health care provider staff (vaccine managers, assistant vaccine		
	managers) to assure accountability across the > 300 enrolled provider practices.	\$96,422.00	\$57,853.20
Vaccine Quality Specialist	, , , , , , , , , , , , , , , , , , , ,		
	Conducts VFC site visits with enrolled health care providers. Conducts on-site training for new Vaccine		
	Managers; offers educational programs related to overall vaccine management, including storage and		
	handling. Reviews all health care provider vaccine management (including emergency) plans;		
	coordinates annual vaccine provider enrollment process, reviewing all health care provider agreements.	\$85,842.00	\$51,505.20
Program Specialist II	Under the direction of the Vaccine Accountability Coordinator, adhering to the standards of vaccine		
	accountability and the VFC Operations Policy & Procedures, this position is responsible for working in		
	the Vaccine Ordering Management System (VOMS/IIS); working with health care provider vaccine		
	ordering-related documents, including vaccine orders, temperature logs and applicable reports. This		
	position works directly with health care providers and staff related to overall vaccine management,		
	including assistance with temperature excursions, vaccine ordering questions, VOMS Help Desk		
	questions and VOMS education and training.	4=0.400.00	4.5.55.00
Immunication Information Contract Ct. (C.C.)	This positions are water the technical aumount Halp Deel, for the Vereira Coderina Maria	\$79,420.00	\$47,652.00
Immunization Information System Staff (2)	This positions operates the technical support Help Desk for the Vaccine Ordering Management System.		
	Interacts with VTrckS (CDC vaccine ordering system) as it relates to the ExIS connection (VOMS) that		
	passes information between the two systems. Works with both systems to assure data quality and		
	vaccine ordering accountability. Works directly with medical health care provider practices to assure		
	education for staff. Develops interoperabilty processes to inform evidence-based strategies.	\$185,496.00	\$111,297.60
	Total	\$807,243.00	\$484,345.80

NHVA Vaccine Association FY2022 Administrative Budget — Adopted by Board June 16, 2021

		Jul 21	4	lug 21	S	Sep 21	(Oct 21	1	Nov 21	ı	Dec 22	J	Jan 22	F	eb 22	IV	lar 22	Apr 22	N	/lay 22	J	un 22	Е	Y2022 Budget Total
EX	PENSE																								
	Administrative Fees	\$ 8,750	\$	8,750	\$	8,750	\$	9,083	\$	9,083	\$	9,083	\$	9,083	\$	9,083	\$	9,083	\$ 9,083	\$	9,083	\$	9,083	\$	107,997
	Subcontractors																								
	Subtotal	\$ 8,750	\$	8,750	\$	8,750	\$	9,083	\$	9,083	\$	9,083	\$	9,083	\$	9,083	\$	9,083	\$ 9,083	\$	9,083	\$	9,083	\$	107,997
	Bank Fees																							\$	-
	Board Meeting Expense	\$ -	\$	-	\$	215	\$	120	\$	120	\$	-	\$	120	\$	-	\$	120	\$ 95	\$	-	\$	120	\$	910
	Stationary and Printing	\$ 35	\$	35	\$	35	\$	35	\$	35	\$	35	\$	35	\$	35	\$	35	\$ 35	\$	35	\$	35	\$	420
	Dues and Subscriptions																							\$	-
	Insurance (D&O)												\$	4,250										\$	4,250
	Licenses and Fees						\$	75																\$	75
	Postage and Shipping	\$ 10	\$	10	\$	10	\$	10	\$	10	\$	10	\$	10	\$	10	\$	10	\$ 10	\$	10	\$	10	\$	120
	Professional Fees - Audit	\$ 3,500			\$	2,350														\$	3,500			\$	9,350
	Professional Fees - Legal	\$ 2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$	2,083	\$ 2,083	\$	2,083	\$	2,083	\$	25,000
	Public Information Expense																							\$	-
	Website				\$	525																		\$	525
	Subtotal	\$ 5,628	\$	2,128	\$	5,218	\$	2,323	\$	2,248	\$	2,128	\$	6,498	\$	2,128	\$	2,248	\$ 2,223	\$	5,628	\$	2,248	\$	40,650
TO	TAL EXPENSE	\$ 14,378	\$	10,878	\$	13,968	\$	11,406	\$	11,331	\$	11,211	\$	15,581	\$	11,211	\$	11,331	\$ 11,306	\$	14,711	\$	11,331	\$	148,647



4. Rate Assumptions and **Assessment Rates**



This Year's Rate Assessment Goals

- Address Historical Swings in Payments to NH DHHS
- Incorporate Concept of Zero Funds Held at NH DHHS
- Address Conclusion of TRICARE Specific Assessments
- Simplify Model Back-End Tool





CY2022 Model Rate Assumptions

(as of September 1, 2021)

- 1. Board commitment to keeping rates stable in future years
- 2. No NHVA funds will be held by NH DHHS to recover in June CY2022
- 3. The TRICARE cap rate* of \$14.82 will continue in CY2022; assessment receivable will be paid down in full in ~four quarters; no revenue in FY2023-24
- 4. Two reserves:
 - 1. 10% reserve of the total non-Federal program cost for the succeeding year (RSA 126-Q:4 II.(c))
 - 2. \$5M assessment reserve fund; can be used for rate stabilization as needed
- 5. No reimbursement of NH DHHS

- Immunization Section administrative cost request of \$484,346 (Tab C)
- 6. The percentage paid by the carriers is 60.0% for CY2022 based on NH DHHS/Federal fund source split
- 7. Interest rate assumptions for cash on hand assume 0.9%
- 8. Total assessed lives have declined 4.4% between CY2014 Q2 and CY2021 Q4 with quarter-to-quarter declines of 0.2% per quarter; model assumes smaller drop in FY2022
- 9. FY2022 CDC credit estimated at \$2.5M*
- 10. Annual 4% administrative budget increase
- 11.No late payment interest assessments

New Hampshire Vaccine Association

SFY2022
-24 Rate
Model
(as of
September
1, 2021)

Draft for Discussion 09.09.2021	Actual	Actual	Actual		Actual	Actual	Forecast	Forecast	Forecast
	SFY17	SFY18	SFY19		SFY20	SFY21	SFY22	SFY23	SFY24
	2016/2017	2017/2018	2018/2019	2	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024
ASSUMPTIONS									
1 Average Annual Covered Lives per Quarter	506,323	499,062	501,634		495,795	487,764	485,000	480,000	475,000
2 Assessment Rate	9.95- 10.30	10.30- 6.70	6.70- 6.47		6.47- 6.80	6.80- 6.25	6.25- 6.85	6.80- 7.75	7.80- 7.95
3 TRICARE Rate	3.33 10.30	10.50 0.70	0.70 0.47		2.47-13.95	13.95-14.82			0.0
RESERVES									
4 10% Reserve (RSA 126-Q:4 II.(c))	\$ 1,965,313	\$ 1,881,915	\$ 1,549,196	\$	1,524,930	\$ 1,505,465	\$ 1,662,525	\$ 1,670,838	\$ 1,679,19
5 Assessment Reserve	. ,,.							\$ 5,000,000	
6 Operational Reserve			\$ 250,000	\$	250,000	\$ 250,000			
7 Remainder Reserves	\$ 2,374,357	\$ 2,071,713			12,553,810		\$ 5,198,515		
TOTAL EXPENSES	\$ 24,657,418	\$ 26,377,918	\$ 26,837,646	\$	26,126,101	\$ 26,067,468	\$ 27,708,757	\$ 27,847,301	\$ 27,986,53
8 Total Government Expended	\$ 11,345,682	\$ 10,622,944	\$ 11,345,682	\$	10,876,797	\$ 11,012,815	\$ 11,083,503	\$ 11,138,920	\$ 11,194,61
9 %	46.01%	40.27%	42.28%		41.63%	42.25%	-		40.00
0 Total NHVA Expended	\$ 13,311,737	\$ 15,754,974	\$ 15,491,964	\$	15,249,304	\$ 15,054,653	\$ 16,625,254	\$ 16,708,381	\$ 16,791,92
1 %	53.99%	59.73%	57.72%		58.37%	57.75%	60.00%	60.00%	60.00
NHVA OUTFLOWS									
2 Total Distributed by NHVA (June Payment)	\$ 19,653,132	\$ 18,819,145	\$ 9,234,656	\$	11,751,393	\$ 11,830,529	\$ 16,625,254	\$ 16,708,381	\$ 16,791,92
3 Administrative Expenses	\$ 175,359	\$ 178,953	\$ 388,786	\$	127,226	\$ 125,713	\$ 148,643	\$ 152,916	\$ 157,40
4 Total Outflows	\$ 19,828,491	\$ 18,998,098	\$ 9,623,442	\$	11,878,619	\$ 11,956,242	\$ 16,773,897	\$ 16,861,297	\$ 16,949,32
NHVA INFLOWS									
5 Assessments	\$ 20,165,670	\$ 18,588,579	\$ 17,796,407	\$	13,390,088	\$ 13,470,273	\$ 12,866,780	\$ 13,584,000	\$ 14,820,00
6 Investment Income	\$ 22,275	\$ 18,168	\$ 357,265	\$	336,301	\$ 75,858	\$ 103,036	\$ 68,800	\$ 39,92
7 Total Inflows	\$ 20,187,945	\$ 18,606,747	\$ 18,153,672	\$	13,726,389	\$ 13,546,131	\$ 12,969,816	\$ 13,652,800	\$ 14,859,92
8 NHVA BEGINNING CASH BALANCE	\$ 3,978,124	\$ 4,339,670	\$ 3,953,627	\$	12,481,766	\$ 7,514,560	\$ 11,448,477	\$ 7,644,396	\$ 4,435,89
9 Outflows	\$ 19.828.491	\$ 18,998,098	\$ 9,623,442	\$	11,878,619	\$ 11,956,242	\$ 16,773,897	\$ 16,861,297	\$ 16,949,32
20 Inflows	\$ 20,187,945	\$ 18,606,747	\$ 18,153,672		13,726,389			\$ 13,652,800	
11 Accrual to Cash Items	\$ 2,092				(796)		-	,,	,,
2 Transfer (to)/from Investments	. ,,,,,	,,,,,,	. (,,,,,,	\$	(6,814,180)				
To Supplement Assessments				Ė		\$ 0			
4 Ending Cash Balance	\$ 4,339,670	\$ 3,953,627	\$ 12,481,766	\$	7,514,560	\$ 11,448,477	\$ 7,644,396	\$ 4,435,899	\$ 2,346,49
5 Ending Investment Balance				\$	6,814,180	\$ 4,466,645	\$ 4,466,645	\$ 4,466,645	\$ 4,466,64
BALANCE HELD AT STATE									
²⁶ Beginning	\$ 9,915,172	\$ 9,915,172	\$ 12,979,343	\$	6,722,035	\$ 3,224,124	\$ -	\$ -	\$ -
7 Additions/Subtractions	\$ 6,341,395	\$ 3,064,171	\$ (6,257,308)	\$	(3,497,911)	\$ (3,224,124)	\$ -	\$ -	\$ -
	\$ 16,256,567	\$ 12,979,343	\$ 6,722,035	\$	3,224,124	\$ (0)	\$ -	\$ -	\$ -



Contact

Patrick Miller, MPH

Executive Director, NHVA

pmiller@helmsco.com

603.225.6633 (o)